Searched for
SIDDHARTH MITTAL CEO
Biocon’s Kiran Mazumdar-Shaw chooses niece Claire Mazumdar as successor: ReportBiocon founder Kiran Mazumdar-Shaw has announced her successor. Niece Claire Mazumdar will lead the company. Claire Mazumdar is the founder...- Syngene shares zoom 17% even as firm’s Q4 net profit drops 19% YoY. What's driving the surge?Syngene shares surged despite a 19% YoY decline in Q4FY26 net profit to Rs 148 crore, as earnings rebounded sharply from Rs 15 crore in the...
- Trump's 100% tariff on patented drugs has limited impact on Indian pharma, rising protectionism a concern: Syngene MDThe recent decision by US President Donald Trump to impose a 100 per cent tariff on patented pharmaceutical imports to US is unlikely to ca...
- Biocon names insider Shreehas Tambe as MD & CEO for 5 years as Siddharth Mittal steps downBiocon announced a leadership change. Siddharth Mittal will step down as Managing Director and Chief Executive Officer on March 31. He will...
- Biocon plans to launch generic Wegovy obesity drug in India by 2027, CEO saysBiocon is set to launch generic versions of Wegovy in India and Canada, aiming for market entry by late 2026 or early 2027. This strategic ...
- Biocon gets CDSCO nod for generic diabetes medicationBiocon has secured Indian regulatory approval for its generic Liraglutide drug substance and product, a version of Victoza, for treating Ty...
- Biocon launches diabetes, obesity management drug in UKBiocon has launched Liraglutide, a drug for diabetes and obesity management, in the UK under the brand names Liraglutide Biocon and Biolide...
- Biocon inks licensing, supply pact with Tabuk Pharmaceutical Manufacturing CoBiocon Ltd has signed a licensing and supply agreement with Tabuk Pharmaceutical Manufacturing Company to commercialise its GLP-1 products ...
- Biocon inks licensing, supply pact with South Korea's Handok for chronic weight management productBiocon signs exclusive licensing agreement with Handok for commercialisation of synthetic Liraglutide in South Korea, expanding portfolio t...
- Biocon Q4 Results: Net profit slumps 57% YoY to Rs 135 croreBiocon Q4 Results: Revenue from operations increased 16% year-on-year (YoY) to Rs 2,947 crore in the January-March 2024 period.
- Biocon inks supply, distribution pact with Medix for chronic weight management drug in MexicoBiocon partners with Medix to distribute Liraglutide for chronic weight management in Mexico, offering affordable obesity treatment options...
- Biocon partners Biomm to commercialise diabetes drug in BrazilBiocon has partnered with Brazil-based Biomm SA for the commercialization of its diabetes drug, Semaglutide (gOzempic). Biocon will develop...
- Biocon appoints Peter Bains as Group CEO"I am delighted to welcome Peter to the Biocon Group in the role of Group CEO. Siddharth Mittal, CEO & MD Biocon Limited, Shreehas Tambe, C...
- Biocon acquires Eywa Pharma's US-based plant for $7.7 millionBiocon Limited announced that its wholly-owned subsidiary, Biocon Generics Inc., has acquired Eywa Pharma Inc.’s oral solid dosage manufact...
- Biocon Q4 Results: Cons PAT grows 31% YoY to Rs 313 crore, revenue surges 57%The board has recommended a final dividend payout of Rs 1.50 per share. In FY23, Biocon’s revenue grew almost 37% to Rs 11,174 crore, while...
- Biocon starts clinical study to evaluate efficacy of ItolizumabThis is a phase two randomised, double-blind, parallel-group, placebo and active-controlled (adalimumab), two treatment period study to eva...
- Biocon plunges 5% even as Q1 profit rises 71%Siddharth Mittal, CEO & Managing Director, Biocon, said, “The strong year-on-year growth of the segment was driven by both our API and Form...
- Lio raises Rs 37 cr from Sequoia Capital India, Lightspeed IndiaThe company plans to use the investment primarily to expand its engineering team and increase the number of users of the mobile application
- Biocon elevates Siddharth Mittal as CEO and joint MDMittal takes over from Arun Chandavarkar who retired as chief executive and joint MD of the company on November 30.
- Buy Bharti Airtel, target Rs 378.0 : Siddharth BhamreBuy Bharti Airtel Ltd. at a price target of Rs 378.0 and a stop loss at Rs 344.0 from entry point
Load More
